2023年5月30日

Durham-based 410醫療,醫療設備公司開發新技術和關鍵緊急救護,完成其750萬美元的B係列風險資本融資。資金,最初關閉2022年後期,由Durham-based Hatteras Venture Partners與現有投資者的參與,包括奧蘭多健康企業,OSF醫療和Raleigh-based WakeMed,和新的投資者民謠Wellstar企業和催化劑。融資將用於進一步開發和部署410年醫學的主要產品,LifeFlow,手持設備觸發快速和精確地注入血液,在危重病人靜脈輸液。“很多年前,我被我們無法提供及時的複蘇患者休克,“羅利說醫生馬克Piehl醫學博士聯合創始人兼首席醫療官410醫療。“現在,410年創建以來十年醫療、急救和重症監護臨床醫生使用LifeFlow改善超過20000名患者的護理。我們感謝許多EMS,醫院和軍事合作關係我們已經開發和投資者使這次旅行成為可能,幫助我們影響病人護理的方式。“嚴重膿毒症影響每年超過100萬名成人和兒童在美國和在住院患者死亡的最常見原因。創傷患者死亡的主要原因是小於45歲。在這些和其他條件導致低血壓和休克,快速交付的血液或IV流體可以是一個拯救生命的治療。與傳統的注入方法,然而,臨床醫生往往不能實現及時複蘇或堅持發布指導方針,根據410年醫療。間隙以來由美國食品和藥物管理局在2016年,LifeFlow已經使用在許多衛生保健係統包括奧蘭多健康,健康和Wellstar民謠。 These three systems have invested in 410 Medical through their venture capital arms. “We are enthusiastic about this partnership’s transformative impact on our communities, as we continue our unwavering pursuit of providing exceptional care to those we serve,” said Amit Vashist, M.D., chief clinical officer for Ballad Health and clinical advisor for Ballad Ventures, both based in Johnson City, Tenn. “Incorporating this leading-edge medical device into our pediatric and emergency settings has already made a significant impact in our ability to deliver timely and effective resuscitation to patients in need, elevating their chances of survival and promoting their overall well-being.” Early funding from NC Biotech 410 Medical was founded by Piehl and venture capitalist Luke Roush in 2013. In 2016 the company was awarded a $250,000 Small Business Research Loan by the North Carolina Biotechnology Center. The loan program supports business inception and research critical to developing products, processes or tools with clear commercial potential. 410 Medical raised $3.2 million in Series A venture capital in 2018 to commercialize LifeFlow. North Carolina investors in the funding round included WakeMed Health & Hospitals and the North Carolina Venture Capital Multiplier Fund, managed by Hatteras Venture Partners. The company lists 21 employees on its website. 410 Medical’s name is derived from the calculation of a fluid-delivery goal in treating pediatric septic shock. Barry Teater, NCBiotech Writer